Glycosylation-modified antigens as a tolerance-inducing vaccine platform prevent anaphylaxis in a pre-clinical model of food allergy

• DOI: 10.1016/j.xcrm.2023.101346
• Publication Date: 2023-12-20T15:27:46Z
• Authors: Shijie Cao; Chitavi D. Maulloo; Michal M. Raczy; Matthew Sabados; Anna J. Slezak; Mindy Nguyen; Ani Solanki; Rachel P. Wallace; Ha-Na Shim; D. Scott Wilson; Jeffrey A. Hubbell
• Keywords: Mice; Vaccines; Glycosylation; Animals; Female; Cattle; Lactoglobulins; Milk Hypersensitivity; Anaphylaxis; Article; Food Hypersensitivity; 3. Good health

The only FDA-approved oral immunotherapy for a food allergy provides protection against accidental exposure to peanuts. However, this therapy often causes discomfort or side effects and requires long-term commitment. Better preventive therapeutic solutions are urgently needed. We develop tolerance-inducing vaccine technology that utilizes glycosylation-modified antigens induce antigen-specific non-responsiveness. administered intravenously (i.v.) subcutaneously (s.c.) traffic the liver lymph nodes, respectively, leading preferential internalization by antigen-presenting cells, educating immune system respond in an innocuous way. In mouse model of cow's milk allergy, treatment with β-lactoglobulin (BLG) is effective preventing onset allergy. addition, s.c. administration BLG shows superior safety potential treating existing allergies combination anti-CD20 co-therapy. This platform immunomodulatory strategy prevent treat allergies.